Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

543 ARTÍCULOS , VIENDO DEL 481 AL 495

Alzheimer's disease clinical trial update 2019-2021

Pleen J, Townley R.

J Neurol. 2022 Feb;269(2):1038-1051. doi: 10.1007/s00415-021-10790-5. Epub 2021 Oct 5.

Omega-3 fatty acids and blood-based biomarkers in Alzheimer's disease and mild cognitive impairment: A randomized placebo-controlled trial

Lin PY, Cheng C, Satyanarayanan SK, Chiu LT, Chien YC, Chuu CP, Lan TH, Su KP.

Brain Behav Immun. 2022 Jan;99:289-298. doi: 10.1016/j.bbi.2021.10.014. Epub 2021 Oct 29.

Blood-based biomarkers of agitation in Alzheimer's disease: Advances and future prospects

Tumati S, Herrmann N, Marotta G, Li A, Lanctôt KL.

Neurochem Int. 2022 Jan;152:105250. doi: 10.1016/j.neuint.2021.105250. Epub 2021 Dec 2.

Biomarkers used in Alzheimer's disease diagnosis, treatment, and prevention

Mahaman YAR, Embaye KS, Huang F, Li L, Zhu F, Wang JZ, Liu R, Feng J, Wang X.

Ageing Res Rev. 2022 Feb;74:101544. doi: 10.1016/j.arr.2021.101544. Epub 2021 Dec 18.

Roles of Gut Microbiota in Pathogenesis of Alzheimer's Disease and Therapeutic Effects of Chinese Medicine

Sun YX, Jiang XJ, Lu B, Gao Q, Chen YF, Wu DB, Zeng WY, Yang L, Li HH, Yu B.

Chin J Integr Med. 2022 Nov;28(11):1048-1056. doi: 10.1007/s11655-020-3274-5. Epub 2020 Sep 1.

Galantamine beyond Alzheimer's disease-a fact or artefact?

Naguy A, Husain K, Alamiri B.

CNS Spectr. 2022 Jun;27(3):268-271. doi: 10.1017/S1092852920002229. Epub 2020 Dec 14.

Discontinuation of cholinesterase inhibitor treatment in institutionalised patients with advanced dementia

García-García R, Calleja-Hernández MÁ.

Eur J Hosp Pharm. 2022 May;29(3):145-150. doi: 10.1136/ejhpharm-2019-002106. Epub 2020 Jul 28.

Integrating music-based interventions with Gamma-frequency stimulation: Implications for healthy ageing

Tichko P, Kim JC, Large E, Loui P.

Eur J Neurosci. 2022 Jun;55(11-12):3303-3323. doi: 10.1111/ejn.15059. Epub 2020 Dec 6.

Pharmacogenetic studies in Alzheimer disease

Zúñiga Santamaría T, Yescas Gómez P, Fricke Galindo I, González González M, Ortega Vázquez A, López López M.

Neurologia (Engl Ed). 2022 May;37(4):287-303. doi: 10.1016/j.nrleng.2018.03.022. Epub 2020 Jun 1.

The Alteration of Neurogenesis and Pathological Markers in Alzheimer's Disease After Deep Brain Stimulation

Nassehi B, Kocabicak E, Temel Y, Hescham S.

Turk Neurosurg. 2022;32(4):535-548. doi: 10.5137/1019-5149.JTN.35598-21.2.

A Review on Chitosan in Drug Delivery for Treatment of Neurological and Psychiatric Disorders

Shayganfard M.

Curr Pharm Biotechnol. 2022;23(4):538-551. doi: 10.2174/1389201022666210622111028.

Implication of Covid-19 on Neurological Complications with Specific Emphasis on Alzheimer's and Parkinson's Disease

Sood A, Goyal R, Singh H, Behl T, Arora S, Saini B, Kaur R.

CNS Neurol Disord Drug Targets. 2022;21(3):235-245. doi: 10.2174/1871527320666210820092817.

Squalamine and trodusquemine: two natural products for neurodegenerative diseases, from physical chemistry to the clinic

Limbocker R, Errico S, Barbut D, Knowles TPJ, Vendruscolo M, Chiti F, Zasloff M.

Nat Prod Rep. 2022 Apr 20;39(4):742-753. doi: 10.1039/d1np00042j.

Current Research on Pro-drug Therapies for Parkinson's and Alzheimer's Disease

Huo C, Wu L, Jiang Z, Yang J, Wang Z, Li Y, Qian S.

Med Chem. 2022;18(6):655-666. doi: 10.2174/1573406418666211130150821.

Challenges of repurposing tetracyclines for the treatment of Alzheimer's and Parkinson's disease

Markulin I, Matasin M, Turk VE, Salković-Petrisic M.

J Neural Transm (Vienna). 2022 Jun;129(5-6):773-804. doi: 10.1007/s00702-021-02457-2. Epub 2022 Jan 4.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias